News

November 24, 2020November 24, 2020

PCF Helps Fund 2 Centers of Excellence to Treat Veterans With Prostate Cancer

News

The Prostate Cancer Foundation (PCF) has committed $5 million to support the launch of two new Centers of Excellence that will provide precision medicine treatments to veterans with prostate ... Read more

November 19, 2020November 19, 2020

Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers

News

The Puerto Rico Health Insurance Administration (ASES) has signed an agreement with miR Scientific to evaluate the economic and health benefits of using the miR Sentinel PCC4 Assay, also called ... Read more

November 17, 2020November 17, 2020

AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA

News

An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and ... Read more

November 12, 2020November 12, 2020

UK Study to Assess Causes of Greater Prostate Cancer Risk Among Black Men

News

Enrollment has resumed in a five-year U.K. study investigating genetic factors behind the higher risk of prostate cancer in men of African and Caribbean descent. The study involves researchers ... Read more

November 10, 2020November 10, 2020

European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations

News

The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the DNA repair genes BRCA1 and BRCA2. The approval follows a ... Read more

November 5, 2020November 5, 2020

Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC

News

A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, after its clinical hold was lifted. The U.S. ... Read more

November 3, 2020November 3, 2020

CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial

News

A heavily pretreated patient with metastatic castration-resistant prostate cancer (mCRPC) showed significant benefits, including a 94% decrease in the levels of the prostate-specific antigen (PSA) biomarker, one month after receiving ... Read more

October 29, 2020October 29, 2020

FDA Clears Ezra Prostate AI, a First for Cancer Imaging

News

The U.S. Food and Drug Administration (FDA) has cleared Ezra Prostate AI, an artificial intelligence (AI) program designed to increase the efficiency with which radiologists analyze images of the ... Read more

October 27, 2020October 27, 2020

New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study

News

A trial opened to investigate CFI-400945, by Treadwell Therapeutics, as a potential oral therapy for people with metastatic castration-resistant prostate cancer (mCRPC), the company announced in a press release. It is one ... Read more

October 22, 2020October 22, 2020

ADT Not Needed With Radiation in Favorable Intermediate-Risk PC

News

Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a ... Read more